Survival Benefit of Antiviral Agents for Hepatocellular Carcinoma Patients Treated with Sorafenib.
10.17998/jlc.2016.16.1.23
- Author:
Jeong Han KIM
1
;
Hyung Min YU
;
Yong HWANG
;
Soon Young KO
;
Won Hyeok CHOE
;
So Young KWON
Author Information
1. Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea. 93haan@hanmail.net
- Publication Type:Original Article
- Keywords:
Hepatocellular carcinoma;
Sorafenib;
Antiviral agents
- MeSH:
Antiviral Agents*;
Carcinoma, Hepatocellular*;
Cohort Studies;
Disease-Free Survival;
Hepatitis B;
Humans;
Recurrence;
Retrospective Studies
- From:Journal of Liver Cancer
2016;16(1):23-30
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: Nucleos(t)ide analogues (NAs) help reduce the recurrence rate after the curative treatment of hepatitis B related hepatocellular carcinoma (HCC). Sorafenib has been shown to improve survival of advanced HCC patients. Whether antiviral therapy with NAs could help such patients is unknown. Our aim is to investigate the usefulness of antiviral therapy for advanced-stage HCC treated with sorafenib. METHODS: We performed a retrospective cohort study in advanced-stage HCC patients treated with sorafenib between June 2007 and December 2013. Patients in group A (the non-antiviral therapy group) were treated with sorafenib alone. Those in group B (the antiviral therapy group) were treated with sorafenib and NAs. Progression-free survival (PS) and overall survival (OS) were compared between these two groups. RESULTS: Finally, 23 patients in group A and 40 patients in group B were enrolled in the study. The mean number of days of treatment with sorafenib was 79 (34-231) days and 96 (33-449) days for group A and B, respectively (P=0.286). The mean PS of group A and B was 97 (14-449) days and 51 (0-461) days, respectively (P=0.068). The OS was 154 (44-741) days in group A and 138 (30-1,025) days in group B (P=0.665). PS and OS showed no significant difference between the two groups. CONCLUSIONS: This study shows that there was no significant survival gain of using antiviral therapy in patients with advanced-stage HCC treated with sorafenib. In consideration of cost-effectiveness, antiviral therapy may be not mandatory.
